147 related articles for article (PubMed ID: 38653904)
1. Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study).
Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K; Sugawara M;
Diabetes Ther; 2024 Jun; 15(6):1403-1416. PubMed ID: 38653904
[TBL] [Abstract][Full Text] [Related]
2. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).
Sugawara M; Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K;
Diabetes Ther; 2023 Sep; 14(9):1517-1535. PubMed ID: 37410308
[TBL] [Abstract][Full Text] [Related]
3. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
Scheen AJ
Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
[TBL] [Abstract][Full Text] [Related]
4. Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study).
Hashimoto-Kameda R; Cho KY; Nomoto H; Nakamura A; Omori K; Nagai S; Edagawa S; Kawata S; Takeuchi J; Kameda H; Kurihara Y; Aoki S; Atsumi T; Miyoshi H;
Diabetes Res Clin Pract; 2021 Oct; 180():109069. PubMed ID: 34563585
[TBL] [Abstract][Full Text] [Related]
5. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
Goldenberg RM
Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
[TBL] [Abstract][Full Text] [Related]
6. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
[TBL] [Abstract][Full Text] [Related]
7. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study).
Ishii H; Hayashino Y; Akai Y; Yabuta M; Tsujii S
J Diabetes Investig; 2018 Jan; 9(1):137-145. PubMed ID: 28296349
[TBL] [Abstract][Full Text] [Related]
9. Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.
Ishii H; Suzaki Y; Miyata Y; Matsui S
Diabetes Ther; 2019 Aug; 10(4):1369-1380. PubMed ID: 31214997
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter 2 inhibitors and the risk of venous thromboembolism: A population-based cohort study.
Aloe S; Filliter C; Salmasi S; Igweokpala S; Yu OHY; Tagalakis V; Filion KB
Br J Clin Pharmacol; 2023 Sep; 89(9):2902-2914. PubMed ID: 37183930
[TBL] [Abstract][Full Text] [Related]
11. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes.
Yen FS; Wei JC; Yu TS; Hung YT; Hsu CC; Hwu CM
JAMA Netw Open; 2023 Dec; 6(12):e2348431. PubMed ID: 38117497
[TBL] [Abstract][Full Text] [Related]
12. Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2 Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study.
Kim M; Ha KH; Lee J; Park S; Oh KS; Bae DH; Lee JH; Kim SM; Choi WG; Hwang KK; Kim DW; Cho MC; Kim DJ; Bae JW
Korean Circ J; 2024 May; 54(5):256-267. PubMed ID: 38654455
[TBL] [Abstract][Full Text] [Related]
13. Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study.
Rokszin G; Kiss Z; Sütő G; Kempler P; Jermendy G; Fábián I; Szekanecz Z; Poór G; Wittmann I; Molnár GA
Front Oncol; 2021; 11():725465. PubMed ID: 34778040
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Furusawa S; Nomoto H; Yokoyama H; Suzuki Y; Tsuzuki A; Takahashi K; Miya A; Kameda H; Cho KY; Takeuchi J; Nagai S; Taneda S; Kurihara Y; Nakamura A; Atsumi T;
Diabetes Obes Metab; 2024 Mar; 26(3):961-970. PubMed ID: 38073422
[TBL] [Abstract][Full Text] [Related]
15. Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
Tan X; Liang Y; Gamble C; King A
Diabetes Ther; 2024 Feb; 15(2):427-445. PubMed ID: 38060149
[TBL] [Abstract][Full Text] [Related]
16. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.
Ogunsanmi DO; Harrison AT; Pakker AR; Kovesdy CP; Bailey JE; Surbhi S
J Manag Care Spec Pharm; 2023 Jun; 29(6):699-711. PubMed ID: 37276038
[No Abstract] [Full Text] [Related]
17. Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin.
Fernandes G; Matos JE; Jaffe DH; Beyer G; Yang L; Iglay K; Gantz I; Rajpathak S
Curr Med Res Opin; 2020 Mar; 36(3):377-386. PubMed ID: 31771370
[No Abstract] [Full Text] [Related]
18. Effect of dipeptidyl peptidase-4 inhibitors on glycated hemoglobin levels relies on dietary sodium intake.
Okada S; Okada K; Okada J; Kikkawa K; Yamada E; Saito T; Andou T; Ohshima K
Diabetes Metab Syndr; 2023 Jul; 17(7):102806. PubMed ID: 37343509
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and satisfaction in patients with type 2 diabetes newly initiating oral monotherapy with antidiabetic drugs in Japan: results from the prospective Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND).
Tajima A; Tobe K; Eiki JI; Origasa H; Watada H; Shimomura I; Tokita S; Kadowaki T
BMJ Open Diabetes Res Care; 2022 Dec; 10(6):. PubMed ID: 36585033
[TBL] [Abstract][Full Text] [Related]
20. Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey.
Murayama H; Imai K; Odawara M
Diabetes Ther; 2018 Jun; 9(3):1185-1199. PubMed ID: 29696567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
